Sign in
CompletedNo phase

Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Key facts

Who runs it
Beijing Tsinghua Chang Gung Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
36 people enrolled
Started
17 Feb 2025
Ended
30 Oct 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • intravenously inject with 5-FU (400 mg/m2)
Record updated
6 January 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age 18-75 years old, regardless of gender and race
  • Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment
  • KPS score ≥ 60, with expected survival time more than 12 months
  • The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function
  • No history of allergy to biological products
  • No serious bacterial or viral infection
  • Non-pregnancy and lactation
  • The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment

Who cannot take part

  • Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation
  • Highly allergic or with a history of severe allergies, especially to biological products
  • Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination
  • Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation
  • Patients with systemic infection or severe local infection requiring anti-infection treatment
  • Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs
  • Coagulation disorders (e.g., hemophilia)
  • Infectious diseases (e.g. HIV, RPR, active TB, etc.)
  • Patients with severe autoimmune diseases
  • Any life-threatening disease, physical condition or organ system dysfunction that the researcher believes may damage the safety of subjects and expose the research results to unnecessary risks; Drug-dependent persons
  • T-lymphocyte carcinoma/tumor
  • Pregnant or lactating women, or women who have pregnancy plans within half a year
  • Patients and/or authorized family members who refuse or do not actively sign the informed consent
  • Participants in other clinical studies within 3 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this study is to combine HIPEC regimens with Flura-seq to detect the effects of different HIPEC regimens (cisplatin vs. cisplatin+ docetaxel) on the nascent transcriptome of PMP tumors, so as to quantitatively assess the efficacy of different HIPEC regimens in the early stage, and to lay the foundation for optimizing the HIPEC regimens and exploring new therapeutic targets.

The 2 groups in the trial

  • Cisplatin GroupTreatment being tested

    After completing CRS, the patient will undergo cisplatin HIPEC treatment. Add 120 mg of cisplatin to 3000 ml of physiological saline, heat to 43 ℃, perfuse at a flow rate of 400 ml/min, and perfuse for 60 minutes.

    Treatment: intravenously inject with 5-FU (400 mg/m2)

  • Cisplatin + Docetaxel GroupExisting treatment, for comparison

    After completing CRS, the patient will undergo HIPEC treatment with cisplatin and docetaxel. Add 120 mg of docetaxel and 120 mg of cisplatin to 3000 ml of physiological saline, heat to 43 ℃, perfuse at a flow rate of 400 ml/min, and perfuse for 60 minutes.

    Treatment: intravenously inject with 5-FU (400 mg/m2)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Fluorouracil-labeled Nascent RNA Technology for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei
Record updated
6 January 2026